Piper Sandler is set to host a virtual meeting on July 24 focusing on (AVTX, Financial). This event provides a platform for investors to gain insights and strategies to enhance their investment approaches. Attendees will have the opportunity to explore advanced data and expert analyses aimed at boosting investment confidence. Additionally, participants can take advantage of a special offer: TipRanks Premium services are available at a 50% discount. This service includes access to powerful investing tools and weekly updates through Smart Investor Picks, which are designed to support smarter investment decisions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Avalo Therapeutics Inc (AVTX, Financial) is $30.86 with a high estimate of $48.00 and a low estimate of $15.00. The average target implies an upside of 358.50% from the current price of $6.73. More detailed estimate data can be found on the Avalo Therapeutics Inc (AVTX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Avalo Therapeutics Inc's (AVTX, Financial) average brokerage recommendation is currently 1.3, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Avalo Therapeutics Inc (AVTX, Financial) in one year is $0.07, suggesting a downside of 98.96% from the current price of $6.73. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Avalo Therapeutics Inc (AVTX) Summary page.
